Skip to main content
Biocon Ltd. logo

Biocon Ltd. — Investor Relations & Filings

Ticker · BIOCON ISIN · INE376G01013 LEI · 335800NK3L7QCHLOC198 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2026-06-08 Declaration of Voting R…
Country IN India
Listing BSE.NS BIOCON

About Biocon Ltd.

https://www.biocon.com/

Biocon Ltd. is a global biopharmaceutical company focused on developing innovative therapies for chronic conditions such as diabetes, oncology, and autoimmune diseases. The company specializes in the research, development, and manufacture of high-quality biosimilars, generic active pharmaceutical ingredients (APIs), and novel biologics. Its portfolio includes recombinant human insulin, insulin analogs, and monoclonal antibodies. Biocon leverages an integrated business model encompassing advanced research and development, large-scale manufacturing, and global commercialization. By prioritizing affordable innovation, the company aims to enhance access to life-saving treatments across international markets, including the United States, Europe, and emerging economies. Its technical expertise in microbial fermentation and complex protein engineering supports a robust pipeline of complex therapeutics designed to address unmet medical needs.

Recent filings

Filing Released Lang Actions
Postal Ballot - Outcome
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal filing to stock exchanges (BSE and NSE) under SEBI Listing Regulations, providing detailed voting results and the scrutinizer’s report for resolutions passed by postal ballot. It lists each resolution’s voting breakdown (in favor/against, shares polled, percentages) and refers to a Scrutinizer's Report. This corresponds exactly to Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-06-08 English
Postal Ballot - Scrutinizer''s Report
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a stock exchange filing from Biocon Limited providing detailed voting results and a Scrutinizer’s Report for resolutions passed via postal ballot under SEBI Listing Regulations. It lists the outcome of shareholder votes on various resolutions (e.g., director appointments, remuneration revisions) with vote counts and percentages. This corresponds to a Declaration of Voting Results & Voting Rights Announcement rather than an AGM presentation, financial report, or management discussion. Therefore, it should be classified under DVA.
2026-06-08 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is a formal letter to stock exchanges reporting the voting results and enclosing the Scrutinizer’s Report for resolutions passed via postal ballot (SEBI Listing Regulations, Section 110 of the Companies Act). It presents vote counts and percentages for each resolution. This matches the category for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-08 English
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)
Regulatory Filings Classification · 85% confidence The document is an exchange filing under SEBI Listing Regulations informing about a schedule of meetings with analysts/institutional investors. It does not contain financial results, presentations, or detailed report data. It serves as a generic regulatory announcement to stock exchanges rather than an earnings release, report, or management change notice. Therefore it falls under the general Regulatory Filings category (RNS).
2026-06-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 92% confidence The document is a stock exchange filing under Regulation 30 of the SEBI Listing Regulations notifying the schedule of analyst/institutional investor meetings. It does not contain financial results, detailed investor presentations, or actual report content. It is a routine regulatory disclosure under listing obligations, fitting the “Regulatory Filings” category (RNS).
2026-06-08 English
Investor Presentation
Investor Presentation Classification · 92% confidence The document is a Biocon Limited letter dated June 1, 2026 addressed to stock exchanges enclosing a detailed slide deck titled “Investor Presentation” with financial metrics, strategy, market position, debt refinancing, acquisitions, R&D and commercial highlights. It contains typical presentation slides for analysts and institutional investors, not a regulatory announcement of results or an earnings release. Therefore it is classified as an Investor Presentation.
2026-06-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.